The purpose of this study was to determine the optimal schedule of i.v. granisetron and dexamethosone for control of nausea and emesis in patients receiving high-dose chemotherapy (HDC). Seventy patients with breast cancer received high-dose cyclophosphamide, thiotepa and carboplatin (CTCb) for 3 consecutive days. All 70 received dexamethasone 12 mg i.v. and granisetron 1 mg i.v. prior to infusion of CTCb and were randomized to receive placebo (n = 37) or an additional identical dose of granisetron (n = 33) 12 h later. Beginning on day 2 of chemotherapy administration, 55 patients evaluable later self-administered a cocktail of diphenhydramine (benadryl), lorazepam (ativan) and dexamethasone (BAD). Fourteen of 37 patients (38%) receiving granisetron once a day and 15/33 (44%) receiving it twice a day had a complete response during the first 24 h following the first doses of chemotherapy (P = 0.52). In the 55 evaluable patients receiving BAD, 18 of 29 (62%) in the once daily group and 14/26 (54%) in the twice daily group required additional medications (P = 0.54). The median time to first emetic episode was 20 h (range 6.6-79.5) for patients receiving once a day and 21.4 hours (range 5.8-105.3) for patients receiving twice a day granisetron (P = 0.48). Five patients in the once daily and seven patients in the twice daily group had complete control of nausea and emesis throughout the study period (P = 0.37). It was concluded that there were no statistically significant differences in nausea and emetic control between dexamethasone with once daily or twice daily i.v. granisetron administration in patients receiving high-dose CTCb.
order to make this form of therapy widely applicable and cost-effective, outpatient administration of chemotherapeutic agents is a necessity. Nausea and vomiting, however, remain significant side-effects which limit the ability to conveniently administer HDC in an outpatient setting.
Granisetron is a selective serotonin 3 , 5-hydroxytrytamine 3 , receptor antagonist which has significant anti-emetic activity against chemotherapy-induced nausea and vomiting. The effects of granisetron for the prevention of nausea and vomiting induced by anti-neoplastic therapy have been reviewed. 5 A single prophylactic intravenous (i.v.) or oral dose is sufficient to control acute nausea and vomiting in approximately 60-70% of patients. 5 Granisetron is usually administered concomitantly with dexamethasone which improves the acute anti-emetic efficacy by approximately 15%. 6, 7 Granisetron has been utilized to prevent nausea and vomiting in patients receiving total body irradiation as conditioning for bone marrow transplantation. 8 There are currently no reports, however, of granisetron for the prevention of nausea and vomiting for patients undergoing HDC and stem cell infusion.
High-dose cyclophosphamide, thiotepa and carboplatin (CTCb) with PBSC support has been used to treat patients with breast cancer in an outpatient setting. 3, 4 The administration of dexamethasone with granisetron as a single i.v. dose would have advantages over currently used anti-emetics which require multiple dosing in a 24 h period. Granisetron, however, has not been previously evaluated in patients receiving HDC and it is not clear that a single daily dose of granisetron with dexamethasone would be adequate to prevent nausea. Before comparing granisetron with other anti-emetics in patients receiving HDC a trial was carried out to determine if daily i.v. dosing was adequate. The current study compared the efficacy of administering one vs two daily doses of granisetron i.v. with dexamethasone for the management of nausea and emesis induced by highdose CTCb.
Patients and methods
Between April 1995 and May 1997, 71 patients with breast cancer were enrolled in a randomized trial of i.v. granisetron with dexamethasone. Patients were eligible for randomization if they had stages II-III or metastatic breast cancer, were scheduled to receive CTCb with PBSC support, were between the ages of 18 and 65, had an ECOG performance status of 0-1, had у2. 
Study design
This was a randomized phase III double blind placebo controlled study with patients being randomized in a one-toone ratio between two treatment groups. Patients were stratified by stage of breast cancer and treatment center.
Dexamethasone: All patients received dexamethasone 12 mg, i.v. 30 min prior to the administration of chemotherapy on each of 3 consecutive days.
Once daily granisetron group: Patients randomized to this group received granisetron 1 mg i.v over 15 min beginning 30 minutes prior to administration of chemotherapy on each of 3 consecutive days. Placebo was infused i.v. over 15 min 12 h after the first dose of granisetron.
Twice daily granisetron group: Patients randomized to this group received the same dose and schedule as above except that placebo was replaced by 1 mg of granisetron.
Other anti-emetic drugs
After the first 13 patients were accrued a preliminary analysis indicated poor emetic control in both groups of patients. Thus, all further patients (n = 55) received a cocktail of diphenhydramine (benadryl) (200 mg), lorazepam (ativan) (8 mg) and dexamethasone (20 mg) (BAD) i.v. via an infusion pump at a constant rate of 0.2-0.4 ml/h beginning after the administration of chemotherapy on day 2. A 2.0-4.0 ml bolus dose could be self administered by the patient every 15 min for nausea and/or vomiting. Additional antiemetic medications could only be given after a significant emetic episode or profound degree of nausea. For purposes of this study, 'additional' medication was defined as drugs other than specified above given specifically to treat nausea or emesis. 
High-dose chemotherapy (CTCb)
Cyclophosphamide
Record keeping
Patients were given a daily worksheet to record time of the first emesis and/or nausea, incidence and severity of nausea, and the number of emetic episodes to day 6 of the study. Adverse events were also reported to the study nurse and included in the case report form.
Endpoints and definitions of response
The primary endpoint was response to granisetron in the first 24 h. Secondary endpoints were: time to first emetic episode; incidence, frequency, and duration of additional anti-emetic agents; severity of nausea over a 6 day period.
The definitions of response were similar to those of the Granisetron Study Group: 10 Complete response was no emesis and no or only mild nausea. Major response was 1-2 emetic episodes with moderate to severe nausea. Minor response was defined as three emetic episodes. Failure was у4 emetic episodes.
The time to the first emetic episode was defined as the period of time between administration of the first dose of granisetron to the time the patient experienced one of the following: any number of retches in a 5 min period, or two or more vomits in close succession not relieved by a period of relaxation, or retching of less than 5 min combined with a single episode of vomiting, or a single episode of vomiting. Each episode was separated by the absence of vomiting or retching for at least 1 min.
A major endpoint was the utilization of additional agents for control of nausea and emesis.
Statistics
Data were collected using a custom designed distributed data system, reviewed at a central clinical trials center (ROI) and analyzed using the SAS system (SAS Institute, Cary, NC, USA). Time to first emetic episode was plotted using the method of Kaplan and Meier 11 and results were compared using a log-rank test. 12 Proportions were compared using an adjusted 2 test of Fisher's exact test depending upon sample size. Mean values were compared using Student's t-test.
Results

Patient characteristics (Table 1)
Patient characteristics are shown in Table 1 .
Protocol compliance
Seventy of 71 patients were eligible for the study. One patient was ineligible due to a history of nausea immediately prior to treatment and was excluded from analysis. Two patients were not evaluable because of non-compliance after one and two doses of study drug, respectively. All 70 patients were included in the analysis of day 1 antiemetic response and 68 were evaluable for subsequent response.
Fifty-five of 68 evaluable patients received BAD on days 2-5.
Effects of dexamethasone and granisetron in the first 24 h following day 1 chemotherapy
The number of patients achieving complete, major and minor responses were 15 (45%), 14 (43%) and 2 (6%), respectively, for the twice daily group and 14 (38%), 15 (41%) and 2 (5%) for the once daily group. The difference in complete response rate between the twice daily and the once daily granisetron group was not statistically significant (P = 0.52). Fifty-five per cent of patients in the twice daily and 58% in the once daily granisetron group required additional medications for control of nausea and vomiting after initiation of chemotherapy (P = 0.85).
Effects of dexamethasone and granisetron following days 2 and 3 chemotherapy
Thirteen patients enrolled in the study did not receive prophylactic BAD during the 6 day study period. Three of five on the twice daily and 8/8 on the once daily schedule of granisetron required additional medications to control nausea and emesis at some time from days 2 to 5 (P = 0.13).
Effects of dexamethasone, granisetron and BAD following days 2 and 3 chemotherapy
The proportions of patients requiring additional anti-emetic medications for the control of nausea and vomiting from Figure 1 shows the probability of time to first emetic episode for all 70 patients (P = 0.48).
Discussion
In this study the effects of once daily or twice daily granisetron on nausea and vomiting following HDC with CTCb were evaluated. In the first 24 h after the first dose of CTCb no other anti-emetics were administered prophylactically. Forty-one per cent of patients receiving twice daily and 38% receiving once daily granisetron had complete control of emesis during the first 24 h after day 1 chemotherapy (P = 0.52) Following day 2 chemotherapy, 13 patients entered on this study did not receive prophylactic treatment with BAD and 11/13 required additional medications for control of nausea and vomiting, 3/5 in the twice daily and 8/8 in the once daily granisetron groups (P = 0.13). These small numbers preclude any meaningful comparisons between the two groups.
For the subsequent 55 evaluable patients, BAD was administered prophylactically, in addition to granisetron and dexamethasone. Following days 2 and 3 chemotherapy, 54% of patients on the twice daily and 62% on the once daily granisetron schedule required additional medications for control of nausea and emesis (P = 0.54).
In all analyses performed there were no statistically significant differences in the control of nausea and emesis between patients receiving once daily or twice daily granisetron. Results from a large multi-center, randomized, double-blind study conducted in 930 patients receiving moderately emetogenic chemotherapy indicated that twice daily administration of an oral dose of 1 mg of granisetron was more effective than once daily administration. 13 Recent data from 697 chemotherapy naïve patients who received moderately emetogenic chemotherapy, however, have suggested that a single 2 mg dose of oral granisetron given 1 h before chemotherapy was as effective as 1 mg given 1 hour before and 12 h following chemotherapy. 14 In the current study there were only slight trends toward more effectiveness of the twice daily dosing as compared to the once daily dosing of granisetron. It is possible that larger numbers of patients in each group would uncover significant differences between the two dose schedules. However, with the numbers of patients involved in the current study no advantage could be detected for the twice daily dosing.
